The skinny on ICD leads
This article was originally published in The Gray Sheet
Executive Summary
St. Jude received FDA approval for its Riata ST lead, firm announces April 10. At 6.3 Fr, Riata ST makes navigation through the vasculature easier for the physician, facilitating more precise lead placement and more effective implantable cardioverter defibrillator therapy, the firm claims. Riata ST also boasts an innovative coil design to prevent tissue in-growth and ease device explantation. St. Jude launches the new lead in the U.S. April 17...